JANX (Janux Therapeutics) Total Receivables: $42.46 Mil (As of Mar. 2026)


JANX Janux Therapeutics Inc JANX
46 GF Score
Price $16.75
GF Value $41.14
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Janux Therapeutics Total Receivables?

Janux Therapeutics JANX +0.54% 46 Total Receivables is $42.46 Mil as of Mar. 2026. GuruFocus rates JANX with a GF Score™ of 46/100 and a GF Value™ of $41.14 (Possible Value Trap). The stock has 5 warning signs investors should review.

Janux Therapeutics's Total Receivables for the quarter that ended in Mar. 2026 was $42.46 Mil.

Janux Therapeutics Total Receivables Related Terms

Janux Therapeutics Total Receivables Historical Data

* Premium members only.

The historical data trend for Janux Therapeutics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Janux Therapeutics Total Receivables Chart

Janux Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial 0.00 0.00 2.16 5.38 6.43

Janux Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.59 5.69 6.32 6.43 42.46
JANX
46GF Score
Janux Therapeutics Inc JANX
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Janux Therapeutics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $42.46 Mil mean?
Janux Therapeutics (JANX) has a Total Receivables of $42.46 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Janux Therapeutics and its competitors.
Is Janux Therapeutics' Total Receivables too high?
Janux Therapeutics' current Total Receivables is $42.46 Mil. Overall, Janux Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Janux Therapeutics' Total Receivables compare to SLDB and TBPH?
Janux Therapeutics' Total Receivables of $42.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Janux Therapeutics and its competitors. Janux Therapeutics's current Total Receivables is $42.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Janux Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Janux Therapeutics (JANX) is currently considered Possible Value Trap. The stock's GF Value™ is $41.14, compared to a current price of $16.75 — trading 59.3% below its estimated fair value. The current Total Receivables is $42.46 Mil. Janux Therapeutics' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Janux Therapeutics (JANX), the current Total Receivables is $42.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Janux Therapeutics (JANX) Overvalued in 2026?

Based on GuruFocus' analysis, Janux Therapeutics stock appears to be undervalued. The current stock price of $16.75 is trading 59.3% below its estimated GF Value™ of $41.14. GuruFocus considers Janux Therapeutics to be Possible Value Trap.

Key valuation signals for JANX:

  • Total Receivables: $42.46 Mil
  • GF Value™: $41.14 vs. price of $16.75 (59.3% below fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the JANX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Janux Therapeutics Business Description

Address 10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
46GF Score

Get the complete analysis for JANX

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.75
Price
$41.14
GF Value